利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.031 秒)

    Dosing Regimen of Flavopiridol for Treating Cancer
    1.
    发明申请
    Dosing Regimen of Flavopiridol for Treating Cancer 审中-公开
    黄酮类药物给药方案治疗癌症

    公开(公告)号：US20110251240A1

    公开(公告)日：2011-10-13

    申请号：US12970550

    申请日：2010-12-16

    申请人： Jose-Ramon SUAREZ ,  John BYRD ,  Michael GREVER ,  James DALTON ,  Thomas LIN

    发明人： Jose-Ramon SUAREZ ,  John BYRD ,  Michael GREVER ,  James DALTON ,  Thomas LIN

    IPC分类号： A61K31/453 ,  A61P35/00

    CPC分类号： A61K31/453 ,  A61K9/0019

    摘要： A dosing regimen comprising a therapeutically effective amount of flavopiridol or a pharmaceutically acceptable salt thereof optionally in combination with a pharmaceutically acceptable carrier suitable for bolus infusion and subsequently for infusion is disclosed and claimed. Also disclosed and claimed is a method of treating a variety of cancers in a patient comprising administering to said patient the dosing regimen of the invention.

    摘要翻译： 公开和要求保护的包含治疗有效量的类风素或其药学上可接受的盐的给药方案，其任选地与适合于推注和随后输注的药学上可接受的载体组合。 还公开并要求保护的是治疗患者中各种癌症的方法，包括向所述患者施用本发明的给药方案。

    Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
    2.
    发明申请
    Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia 审中-公开
    可预测慢性淋巴细胞性白血病治疗反应的细胞遗传学异常

    公开(公告)号：US20050191632A1

    公开(公告)日：2005-09-01

    申请号：US10700264

    申请日：2003-11-03

    申请人： John Byrd ,  Nyla Heerema

    发明人： John Byrd ,  Nyla Heerema

    IPC分类号： C12Q1/68 ,  G01N33/574

    CPC分类号： C12Q1/6841 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

    摘要： Methods and kits are provided for predicting the response of patients with B-cell chronic lymphocytic leukemia (CLL) to treatment with agents that bind to the CD20 and CD 52 antigens on the surface of B lymphocytes. The methods of the present invention are for identifying patients who are refractory and patients who are responsive to therapy with such agents by analyzing the genome of cells obtained from the patients for the presence of specific chromosomal abnormalities, including del(17p13.1), and one or more of del(13q14.3), del(11q22.3) and trisomy 12. The methods are performed using appropriate cytogenetic analysis techniques, such as fluorescence in situ hybridization (FISH), with probes capable of detecting the specific cytogenetic abnormalities. Patients without del(17p13.1) but with del(13q14.3), del(11q22.3) or trisomy for chromosome 12, have been shown to be responsive to agents that bind CD20, such as rituximab. Patients with del(17p13.1) have been shown not to be responsive to rituximab, but are responsive to agents that bind CD52, such as alemtuzumab. By customizing treatment of CLL based on a patient's cytogenetic profile, an improved Outcome may be achieved for the patient, along with time and cost savings that are afforded by foregoing unnecessary therapy.

    摘要翻译： 提供方法和试剂盒，用于预测B细胞慢性淋巴细胞性白血病（CLL）患者对结合B淋巴细胞表面CD20和CD52抗原的药物的治疗反应。 本发明的方法是通过分析从患者获得的细胞的基因组中鉴定特异性染色体异常的存在，包括del（17p13.1）和 del（13q14.3），del（11q22.3）和三体性12中的一种或多种。该方法使用适当的细胞遗传学分析技术进行，例如荧光原位杂交（FISH），具有能够检测特异性细胞遗传学异常的探针 。 没有del（17p13.1）但del（13q14.3），del（11q22.3）或染色体12的三体性的患者已被证明对结合CD20的药物如利妥昔单抗有反应。 已证实del（17p13.1）患者对利妥昔单抗不敏感，但对结合CD52的药物（如阿仑单抗）有反应。 通过根据患者的细胞遗传学特征定制CLL的治疗，可以为患者实现改善的结果，以及通过前述不必要的治疗提供的时间和成本节省。

    Dosing Regimen of Flavopiridol for Treating Cancer`
    5.
    发明申请
    Dosing Regimen of Flavopiridol for Treating Cancer` 审中-公开
    黄酮类药物给药方案治疗癌症

    公开(公告)号：US20080027105A1

    公开(公告)日：2008-01-31

    申请号：US11841241

    申请日：2007-08-20

    申请人： Jose-Ramon SUAREZ ,  John BYRD ,  Michael GREVER ,  James DALTON ,  Thomas LIN

    发明人： Jose-Ramon SUAREZ ,  John BYRD ,  Michael GREVER ,  James DALTON ,  Thomas LIN

    IPC分类号： A61K31/452

    CPC分类号： A61K31/453 ,  A61K9/0019

    摘要： A dosing regimen comprising a therapeutically effective amount of flavopiridol or a pharmaceutically acceptable salt thereof optionally in combination with a pharmaceutically acceptable carrier suitable for bolus infusion and subsequently for infusion is disclosed and claimed. Also disclosed and claimed is a method of treating a variety of cancers in a patient comprising administering to said patient the dosing regimen of the invention.

    摘要翻译： 公开和要求保护的包含治疗有效量的类风素或其药学上可接受的盐的给药方案，其任选地与适合于推注和随后输注的药学上可接受的载体组合。 还公开并要求保护的是治疗患者中各种癌症的方法，包括向所述患者施用本发明的给药方案。